Amedisys (AMED): Revenue Not OpEx Tells The Story - Jefferies
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Jefferies analyst, Brian Tanquilut, reiterated his Buy rating on shares of Amedisys (NASDAQ: AMED) but cut his price target to $50 from $59 after a pre-release of weak Q3 EPS.
While pressuring earnings growth and price targets, the misstep seems mostly attributable to disruptions related to the rollout of its new IT system. While the EPS miss is disappointing, reported revenues were actually above consensus, highlighting strength in hospice and personal care. Beyond Q3, the analyst believes the company remains positioned to see healthy organic volume growth and margin expansion once its HCHB rollout is completed at year-end, which sets the stock up for good EPS growth going forward.
Shares of Amedisys closed at $42.55 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Skyworks Solutions (SWKS) PT Raised to $105 at Oppenheimer Following 1Q Report
- Union Pacific (UNP) PT Raised to $120 at Aegis Capital Following Solid 4Q
- UPDATE: SunTrust Robinson Humphrey Downgrades Pennsylvania Real Estate Investment Trust (PEI) to Hold
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change
Related EntitiesJefferies & Co, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!